Jan 23, 2013

Oral drug better for cancer patients

Seventy percent of pancreatic cancer patients who orally take the cancer drug S-1 survive two years after surgery, compared with 53 percent of those who receive the intravenous drug gemcitabine, a medical research group said Wednesday. The group, led by Katsuhiko Uesaka at Shizuoka ...